H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)

March 25, 2026 6:58 AM

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $56.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found